Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of NRL-1 (Valtoco) in Epilepsy
NCT02721069Phase 3Completed
- Sponsor
- Neurelis
- Start
- Apr 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of diazepam nasal spray in epilepsy, Acute repetitive seizures (ARS), sponsored by Neurelis. Started Apr 2016; status: completed.
02
Drugs
diazepam nasal spray
03
Conditions
epilepsyAcute repetitive seizures (ARS)
Beyond the preview
Go deeper on NCT02721069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721069.